ANDREA ESTEBANEZ

Dr. ANDREA ESTEBANEZ

Dermatology, Hospital Universitario Doctor Peset, Valencia, Spain
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
PDF file
ANDREA ESTEBANEZANDREA ESTEBANEZ
ANDREA ESTEBANEZ
LPL Pérez-Santiago
L Pérez-Santiago
ESE Silva
E Silva
SGS Guillen-Climent
S Guillen-Climent
AGA García-Vázquez
A García-Vázquez
MRM D Ramón
M D Ramón
We have read with great interest Dr Recalcati’s review about skin manifestations in COVID‐19 as it is the first report on this subject1. In a recent review on clinical characteristics of coronavirus disease 2019 in China, rash was observed in 0,2% of cases2. However, from the trained eyes of a dermatologist, this percentage may be higher.

1 January 2019 in International Journal of Trichology
Verified
Journal Article
Closed access
ANDREA ESTEBANEZANDREA ESTEBANEZ
ANDREA ESTEBANEZ
NENuria Estébanez
Nuria Estébanez
JMJoseM Martín
JoseM Martín
EMEncarna Montesinos
Encarna Montesinos
Alopecia areata (AA) is a common disease characterized by nonscarring hair loss. There are no satisfactory therapies for extensive cases. Systemic immune suppressants are usually used despite their nonspecific actions and often associated side effects. Apremilast is an oral, small-molecule, inhibitor of phosphodiesterase 4 approved for the treatment of psoriasis and psoriatic arthritis. Its use in AA has shown variable results. Whereas a recent reduced clinical trial concluded a lack of efficacity, several case reports demonstrate a significant improvement. We report four cases of extensive AA successfully treated with apremilast.

29 October 2022 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
FRFrancisco Javier Melgosa Ramos
Francisco Javier Melgosa Ramos
RRRamón García Ruiz
Ramón García Ruiz
ANDREA ESTEBANEZANDREA ESTEBANEZ
ANDREA ESTEBANEZ
APAlmudena Mateu Puchades
Almudena Mateu Puchades

22 April 2020 in Pediatric Dermatology
Verified
Journal Article
Closed access
PDF file
ANDREA ESTEBANEZANDREA ESTEBANEZ
ANDREA ESTEBANEZ
LSLuis Carlos Sáez‐Martín
Luis Carlos Sáez‐Martín
JMJuan Ignacio Muñoz
Juan Ignacio Muñoz
ESEsmeralda Silva
Esmeralda Silva
AMAlicia Monrabal
Alicia Monrabal
MRMaría Dolores Ramón
María Dolores Ramón

22 June 2020 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
EDEsmeralda Silva Díaz
Esmeralda Silva Díaz
MMMaria Odile Molini Menchón
Maria Odile Molini Menchón
ANDREA ESTEBANEZANDREA ESTEBANEZ
ANDREA ESTEBANEZ
AGAlejandro Garcia‐Vázquez
Alejandro Garcia‐Vázquez
JCJavier Estañ Capell
Javier Estañ Capell
JHJose Martín Hernández
Jose Martín Hernández

11 August 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JLJavier Loricera
Javier Loricera
CBCARMEN BEJERANO
CARMEN BEJERANO
ANDREA ESTEBANEZANDREA ESTEBANEZ
ANDREA ESTEBANEZ
IGIrene García
Irene García
NMNasser Mohammad
Nasser Mohammad
RBRicardo Blanco
Ricardo Blanco
Objective: Anifrolumab is approved for systemic lupus erythematosus (SLE). Its off-label use in non-systemic cutaneous lupus erythematosus (NSCLE) remains poorly characterized. We aimed to assess its effectiveness and safety in refractory NSCLE, supported by a literature review and exploratory immunologic analysis. Methods: This multicenter observational study included patients with NSCLE treated with anifrolumab. Skin disease was assessed using the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI). CLASI scores at baseline were compared to months 1, 3, and 6. A narrative literature review was also conducted. In a subset of three patients, peripheral blood immunophenotyping was performed before and after treatment to explore immunologic surrogate markers associated with clinical response. Results: Fifteen patients (11 women; mean age 52.1 ± 11.7 years) were included. All had received topical corticosteroids and hydroxychloroquine. Most of them had failed multiple systemic therapies. Anifrolumab (300 mg IV every 4 weeks) was used in combination (n = 12) or as monotherapy (n = 3). All patients improved. Median CLASI-A decreased from 16 to 1 (p < 0.001); CLASI-D decreased from 5 to 4 (p < 0.001). The literature review identified 6 publications reporting 14 additional cases of NSCLE with similar outcomes and minimal adverse effects. Immunologic profiling pointed to an increase in intermediate and non-classical and decreased PD-1 expression in monocytes and NK cells after 12 weeks of treatment. Conclusions: Anifrolumab appears effective and relatively safe in refractory NSCLE. Preliminary immunologic data suggest changes in peripheral blood monocyte subsets and NK cells. However, these findings must be confirmed in prospective, controlled clinical trials.